Rockwell Medical, Inc. Announces Presentations at the American Society of Nephrology Virtual Kidney Week 2020
Rockwell Medical (Nasdaq: RMTI) announced that two abstracts have been accepted for poster presentations at the ASN Virtual Kidney Week 2020 from October 20 to 25. The abstracts focus on the use of Triferic in hemodialysis patients, highlighting its role in maintaining hemoglobin levels and reducing the need for IV iron. Triferic is FDA-approved and aims to transform iron deficiency treatment in end-stage kidney disease patients.
- Two abstracts accepted for presentation at ASN Virtual Kidney Week 2020, highlighting the efficacy of Triferic.
- Triferic is the only FDA-approved therapy to replace iron and maintain hemoglobin in hemodialysis patients.
- Presentations may enhance visibility and credibility of Rockwell Medical's product portfolio.
- None.
WIXOM, Mich., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that two abstracts have been accepted for poster presentation at the American Society of Nephrology (ASN) Virtual Kidney Week 2020, which will occur from October 20 to 25, 2020.
Title: Use of Triferic and Outcomes of HDD Patients: Initial Analysis Using 2016-2017 USRDS
Presenter: Yi Zhang, Ph.D., Sr. Research Associate, Medical Technology and Practice Patterns Institute
Session Title: Hemodialysis and Frequent Dialysis - 4
E-Poster Number: PO1213
Abstract Number: 3450928
Title: Triferic (ferric pyrophosphate citrate, FPC) Maintains Hemoglobin and Reduces IV Iron: Results from a Single-site 2 Year Observational Analysis
Presenter: Marc Hoffman, M.D., Chief Medical Officer, Rockwell Medical
Session Title: Anemia and Iron Management
E-Poster Number: PO0225
Abstract Number: 3440944
About Rockwell Medical
Rockwell Medical is a biopharmaceutical company dedicated to transforming iron deficiency and anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company’s initial focus is the treatment of anemia in end-stage kidney disease (ESKD). Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and Triferic AVNU, are the only FDA-approved therapeutics indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.
About Triferic Dialysate and Triferic AVNU
Triferic Dialysate and Triferic AVNU are the only FDA-approved therapies in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic Dialysate and Triferic AVNU have a unique and differentiated mechanism of action, which has the potential to benefit patients and health care economics. Triferic Dialysate and Triferic AVNU represent a potential innovative medical advancement in hemodialysis patient iron management – with the potential to become the future standard of care.
Triferic Dialysate and Triferic AVNU both deliver approximately 5-7 mg iron with every hemodialysis treatment to the bone marrow and maintain hemoglobin without increasing iron stores (ferritin). Both formulations donate iron immediately and completely to transferrin (carrier of iron in the body) upon entry into the blood which is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no reports of anaphylaxis in over 1,200,000 patient administrations, addressing a significant medical need in overcoming Functional Iron Deficiency (FID) in ESKD patients.
Important Safety Information
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in 1 (
Iron status should be determined on pre-dialysis blood samples. Post dialysis serum iron parameters may overestimate serum iron and transferrin saturation.
The most common adverse reactions (≥
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements relating to the abstract accepted for poster presentations. Words such as, “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “can,” “would,” “develop,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical’s SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to: market and other conditions, the impact of the COVID-19 pandemic (including federal or state orders) on business and operating results; and those risks more fully discussed in the “Risk Factors” section of our Quarterly Report on Form 10-Q for the period ended June 30, 2020 and of our Annual Report on Form 10-K for the year ended December 31, 2019, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.
Triferic® is a registered trademark of Rockwell Medical, Inc. Triferic AVNU is pending with the U.S. Patent and Trademark Office. All other product names, logos, and brands are property of their respective owners in the United States and/or other countries. All company, product and service names used on this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.
CONTACTS
Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
FAQ
What abstracts were accepted for presentation by Rockwell Medical at ASN Kidney Week 2020?
When is the ASN Virtual Kidney Week 2020 where Rockwell Medical will present?
What is Triferic and its significance in hemodialysis?
What are the expected outcomes of the Triferic presentations at ASN Kidney Week 2020?
